Drug Profile
DRL 11605
Alternative Names: DRF 11605; DRL-11605Latest Information Update: 26 May 2009
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories; Perlecan Pharma
- Developer Perlecan Pharma
- Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 26 May 2009 Discontinued - Phase-I for Obesity in Canada (unspecified route)
- 21 Mar 2007 Discontinued - Preclinical for Lipid metabolism disorders in India (unspecified route)
- 21 Mar 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in India (unspecified route)